[Form 4] PMV Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

PMV Pharmaceuticals (PMVP) reported an insider transaction by its President and CEO (also a Director). On 10/27/2025, he exercised an employee stock option and acquired 220,643 shares of common stock at $1.37 per share.

Following the transaction, he beneficially owned 451,109 shares directly, plus indirect holdings of 165,307, 453,582, and 56,978 shares held by family trusts. The exercised option covered 220,643 shares and now has 0 remaining.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mack David Henry

(Last) (First) (Middle)

C/O PMV PHARMACEUTICALS, INC.

400 ALEXANDER PARK DRIVE, SUITE 301

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/27/2025		M		220,643	A	$1.37	451,109(1)	D
Common Stock								165,307	I	See footnote(2)
Common Stock								453,582(3)	I	See footnote(4)
Common Stock								56,978	I	See footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.37	10/27/2025		M			220,643	(6)	11/16/2026	Common Stock	220,643	$0	0	D

Explanation of Responses:

1. Excludes 305,667 shares previously reported as held directly by the reporting person which were re-registered on August 13, 2025 and are now held of record by the Mack-Mulligan Revocable Trust (the "Revocable Trust").

2. The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

3. Includes 305,667 shares previously reported as held directly by the reporting person which were re-registered on August 13, 2025 and are now held of record by the Revocable Trust.

4. The shares are held of record by the Revocable Trust.

5. The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

6. The shares subject to the option are fully vested and immediately exercisable.

	/s/ Robert Ticktin, by power of attorney	10/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PMVP disclose?

On 10/27/2025, the President and CEO exercised an employee stock option and acquired 220,643 PMVP common shares at $1.37 per share.

How many PMVP shares did the insider own after the transaction?

Following the transaction, direct ownership was 451,109 shares, with additional indirect holdings of 165,307, 453,582, and 56,978 shares held by trusts.

What happened to the employee stock option after the exercise?

The option covering 220,643 shares was fully exercised and shows 0 derivative securities remaining.

What was the exercise price of the option?

The exercise price was $1.37 per share.

What roles does the reporting person hold at PMV Pharmaceuticals (PMVP)?

He is a Director and serves as President and CEO.

Who holds the indirect PMVP share positions?

They are held by the Stinson 2021 Irrevocable Trust, the Mack-Mulligan Revocable Trust, and the Mack/Mulligan 2020 Irrevocable Descendants' Trust as disclosed.